13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $183M | 91.4% | -712.7% | -$5M | — | $48M |
| 2024 | $30M | -$48M | 47.5% | -507.8% | -$138M | — | $50M |
| 2023 | $47M | -$284M | 91.5% | -689.5% | -$318M | — | $82M |
| 2022 | $141M | -$294M | 85.6% | -213.9% | -$150M | — | $156M |
| 2021 | $235M | -$290M | 94.5% | -122.6% | -$87M | — | $171M |
| 2020 | $176M | -$189M | 95.0% | -108.8% | $78M | — | $678M |
| 2019 | $257M | -$77M | 99.6% | -34.8% | -$84M | — | $126M |
| 2018 | $213M | -$86M | 0.0% | -40.7% | -$84M | — | $89M |
| 2017 | $131M | -$121M | 0.0% | -89.5% | -$75M | — | $674M |
| 2016 | $183M | -$58M | 0.0% | -27.3% | $6M | — | $174M |
| 2015 | — | -$86M | — | — | — | — | $153M |
| 2014 | — | -$60M | — | — | — | — | $165M |
| 2013 | — | -$15M | — | — | — | — | $76M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $4M | -$15M | -9.8% | -369.7% | -$14M | — | $37M |
| Dec '25 | $1M | -$14M | 78.2% | -1058.1% | -$18M | — | $48M |
| Sep '25 | $1M | $201M | 105.4% | -502.9% | -$2M | — | $118M |
| Jun '25 | $1M | -$8M | 93.7% | -894.1% | $13M | — | $23M |
| Mar '25 | $3M | $5M | 90.8% | -544.7% | $3M | — | $34M |
| Dec '24 | $3M | $18M | 286.5% | -227.5% | -$31M | — | $50M |
| Sep '24 | $123000 | -$17M | 161.0% | -38774.0% | -$8M | — | $131M |
| Jun '24 | $998000 | -$16M | 86.0% | -4650.1% | -$40M | — | $141M |
| Mar '24 | $25M | -$33M | 15.9% | -193.9% | -$59M | — | $106M |
| Dec '23 | -$74M | -$56M | 87.2% | 128.8% | -$19M | — | $82M |
| Sep '23 | $40M | -$64M | 89.4% | -158.2% | -$85M | — | $121M |
| Jun '23 | $44M | -$88M | 87.1% | -198.7% | -$112M | — | $153M |
| Mar '23 | $36M | -$77M | 90.3% | -210.4% | -$102M | — | $189M |
| Dec '22 | $34M | -$66M | 85.7% | -192.5% | -$53M | — | $156M |
| Sep '22 | $16M | -$92M | 72.6% | -595.2% | -$53M | — | $156M |
| Jun '22 | $30M | -$73M | 77.2% | -262.4% | -$34M | — | $168M |
| Mar '22 | $61M | -$63M | 93.0% | -103.6% | -$10M | — | $186M |
| Dec '21 | $17M | -$134M | 81.1% | -817.5% | -$56M | — | $171M |
| Sep '21 | $156M | $50M | 97.9% | 32.7% | $43M | — | $275M |
| Jun '21 | $24M | -$134M | 87.4% | -549.3% | -$28M | — | $353M |
How the market has priced KYNB against its own fundamentals since 2026-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, KYNTRA BIO, INC.'s revenue has declined 48.4% per year. These are computed facts, not advice.
As of FY2025, KYNTRA BIO, INC. reported — of total debt against $48M of cash; operating income covered interest expense -5.2×.
In FY2025, gross margin was 91.4%, operating margin -712.7%, and net margin 2848.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.